reVax patent has been granted
Basis patent for the target specific tolerance induction by GalCer liposome, reVax technology, has been granted Tokyo, JAPAN–(Nov 28, 2011) – REGiMMUNE Corp. (“Company”) announces that the Japanese Patent Office has granted a patent, containing claims for a target specific tolerance induction technology, which we named reVax technology. The issued patent covers the GalCer liposome [...]
Publication of GvHD paper
REGiMMUNE Corp. Announces Publication of preclinical GvHD data Tokyo, JAPAN–(Nov 22, 2010) – REGiMMUNE Corp. (“Company”) is pleased to announce the acceptance and publication of the paper entitled “Pharmacological Expansion of Donor-derived, Naturally Occurring CD4+Foxp3+ Regulatory T Cells Reduces Acute GvHD Lethality without Abrogating GvL in Murine Models.” by the Biology of Blood and Marrow Transplantation(in [...]
REGiMMUNE Presents New ToleroVax Data at the 2010 American Transplant Congress
REGiMMUNE Presents New ToleroVax Data at the 2010 American Transplant Congress San Diego, CA – May 4, 2010 – REGiMMUNE Corporation said today that data from a preclinical study showed an enhanced immune suppression when ToleroVax (RGI-2001), its lead product candidate for the prevention of acute Graft-versus-Host Disease (GvHD), is combined with anti-thymocyte globulin (ATG). [...]
About Press release from RIKEN
About Press release from RIKEN regarding RGI-1001
Entered into a License Agreement with RIKEN
Tokyo, Japan –Sep. 1, 2006 – REGiMMUNE Corporation, a privately held biopharmaceutical company, announced that it has entered into a license agreement with RIKEN. Under the agreement, an exclusive right to market/sublicense pharmaceutical products based on RIKEN’s immune regulating technology is granted to REGiMMUNE from RIKEN. For Information Contact: Yuko Amizaki, Director, Corporate Planning REGiMMUNE. [...]
“REGiMMUNE to file IND of its Tolerance Inducing therapy” : An article is on Nikkei Business Paper today
KRN7000, a synthetic derivative of alpha-galactosylceramide, is a small molecule that potently activates natural killer T (NKT) cells. RGI-2001 is a proprietary liposomal formulation of KRN7000. RGI-2001 has shown to induce antigen-specific immune suppression by inducing regulatory T cells (Tregs). Tregs are believed to play a central role in inducing and maintaining immune tolerance. RGI-2001 [...]
Astellas and REGiMMUNE to Collaborate on New Vaccine Technology
Tokyo, Japan and Mountain View, CA – July 22, 2009 – REGiMMUNE Corporation today announced that Astellas Pharma Inc. and REGiMMUNE have entered into a collaboration agreement to jointly research and develop a novel vaccine-platform technology. The partnership will combine Astellas’ broad range of capabilities in screening and developing natural source-derived compounds with REGiMMUNE’s immune liposome [...]
REGiMMUNE Presented Enhanced Efficacy Data in Preclinical Transplantation Models at the 2009 American Transplant Congress
Boston, MA – June 1, 2009 – REGiMMUNE Corporation today announced that its lead product candidate RGI-2001, in combination with a low-dose of Sirolimus, demonstrated enhanced efficacy in transplantation tolerance induction in models of skin transplantation and acute Graft-versus-Host disease (GvHD). This data is being presented today in a poster titled “Donor-Specific Tolerance Induction by [...]
REGiMMUNE Receives $12 Million in Grants to Develop Transplant and Allergy Drugs
Mountain View, CA and TOKYO – December 8, 2008 – REGiMMUNE Corporation, a privately held biopharmaceutical company focused on developing technologies and products for immune disorders, today announced that it has received two separate grants totaling more than $12 million from the Japan Science and Technology Agency (JST) and from National Institute of Biomedical Innovation (NIBIO). [...]
REGiMMUNE to Present at the 50th ASH Annual Meeting
Mountain View, CA – December 5, 2008 – REGiMMUNE Corporation, a privately held biopharmaceutical company focused on developing technologies and products for immune disorders, will present preclinical data on the company’s potential therapeutic treatment for Graft versus Host Disease (GvHD) at the American Society of Hematology Annual Meeting (ASH) being held December 6 through 9 in San Francisco, [...]
revax technology is introduced on the leading Japanese Business Paper, Nikkei
For more information, please contact from this page
NEWS release of “Novel immunotherapy for treatment of cedar allergy”
The release is primarily for Japan but breifly; 1. RIKEN and REGiMMUNE has developed recombinant cedar antigen for treatment of cedar allergy. Because of its unique conformation, it has lower or no risk of anaphylactic shock which is expected for native antige used for desensitization therapy. 2. Animal studies have been conducted and efficacy and [...]
Relocation of Headquarters in Japan
Japan headquarters has been relocated to following address as of August 1st 2008. 1-7-8 Kaigan Tokyo Industrial Trade Center 607 (6th Floor) Minato-ku Tokyo 105-0022 JAPAN for detailed direction, please see accesss page
REGiMMUNE Raises $8,000,000 in Series B Financing
Mountain View, CA and TOKYO – May 6, 2008 – REGiMMUNE Corporation, a privately held biopharmaceutical company, announced today that it has closed its Series B financing for a total of $8 million U.S. Proceeds from the financing will be used to advance the company’s lead program, RGI-2001, to human clinical trials for graft versus host [...]
REGiMMUNE Closes First Tranche of Series B Financing
Mountain View, CA and TOKYO – Feb 1, 2008 – REGiMMUNE Corporation., a privately held biopharmaceutical company, announced today that it has raised a total of $6 million U.S. in a Series B venture capital financing from new and existing investors. The original lead investor NIF SMBC Ventures Co., Ltd. led the round, with the participation [...]